David A. Wiersma
Senior Associate
Wiersma manages development and prosecution of RCT’s pharmaceutical and biologics patent estate, evaluates intellectual property for RCT investment opportunities, and manages a portfolio of commercialized technologies. During his career at RCT, Wiersma has participated in the commercialization of the cisplatinum anticancer agents Platinol® and Paraplatin®, cationic radiopharmaceuticals (Cardiolite®, Myoview™) and the PSA blood test for prostate cancer. His scientific areas of focus at RCT are biologics, diagnostics, oncology, and metabolic disease.
Professional Experience
- Research Corporation Technologies
Senior Associate, 1999-present
Director, Alerion Biomedical Inc., 2004-2007
Director, MetaProbe Inc., 1997-2004
Manager, MetaProbe LLC, 1997
Science Advisory Board, Sertoli Technologies Inc., 1996-2006
Associate, Life Sciences, 1987-1999
Registered U.S. Patent Agent, 1985-present
Research Corporation, 1984-1987 - The University of Arizona
Research Associate, College of Pharmacy, 1982-2006 - Michigan Drug Detection Center
Laboratory Technologist, Grand Rapids, Michigan, 1975-1977
Education
- Michigan State University
Ph.D., Pharmacology - Calvin College
B.S., Biology-Chemistry
Contact
Assistant: Andrea Lance
(520) 748-4468
General: (520) 748-4400